Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

A Double-blind, Randomized Clinical Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04027803

Enrollment

Registered

2019-07-22

Start date

2018-09-21

Completion date

2019-04-07

Last updated

2020-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

Interventions

BIOLOGICALBCD-148

single intravenous infusion of BCD-148 (900 mg)

BIOLOGICALSoliris

single intravenous infusion of Soliris (900 mg)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

1. Signed ICF for participation in the study 2. Men from 18 to 45 years old (inclusive) at the time of signing the ICF 3. BMI within the normal limits (18.0 to 30 kg/m2) 4. The subject is able to follow the Protocol procedures (in the investigator's opinion) 5. The subject is verified as Healthy according to results of standard clinical, laboratory and instrumental tests 6. Normal hemodynamic parameters: systolic BP from 90 mmHg to 130 mmHg; diastolic BP from 60 mmHg to 90 mmHg; HR from 60 bpm to 90 bpm 7. The subject and his sex partner of childbearing potential consent to implement reliable contraceptive methods from the moment the subject signs the ICF and until the subject completes the study. This requirement does not apply to those subjects who had undergone surgical sterilization. Reliable contraception methods mean one barrier method in combination with one of the following: spermicides, intrauterine device and/or oral contraceptives used by the subject's partner. 8. The subject agrees not to drink alcohol for 24 h prior to the infusion of the test/reference drug and for the entire period while the subject is in the study. \-

Exclusion criteria

1. Psychiatric disorders or other conditions that can affect the ability of the subject to follow the study protocol 2. Acute infections within 4 weeks before signing the ICF 3. Results of laboratory and/or instrumental tests are outside the site's normal range 4. Any surgery done within 30 days before the screening or planned within 30 days after the subject completes the study 5. Impossibility to insert an intravenous catheter for blood collection (e.g., because of a skin condition at the venipuncture site) 6. A history of allergies 7. Known hypersensitivity to any component of BCD-148 or Soliris®, murine proteins or other drug components; hypersensitivity to any component of the meningococcal vaccine 8. The subject had used any medications that significantly affect hemodynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days before signing the ICF and/or the subject needs any medications (other than the study drugs) to be taken during the entire study period 9. The subject had previously used eculizumab and/or other therapeutic monoclonal antibodies against complement C5 10. Regular use (oral or parenteral) of any drugs, including OTC products, vitamins or biologically active supplements within 14 calendar days before signing the ICF 11. A history of recurrent/chronic hemorrhages or any hemorrhage within 30 days prior to signing the ICF 12. Acute or chronic infections or other diseases that, in the investigator's opinion, may affect the PK, PD or safety of the study products 13. HIV, HCV, HBV infection, syphilis. 14. Meningococcal infection in the past (documented or mentioned verbally by the subject) 15. Vaccination within 4 weeks before the planned infusion date, except for vaccination against Neisseria meningitidis given to all subjects in the screening period 16. The subject refuses to get a vaccination against Neisseria meningitidis during the screening period . 17. The subject smokes more than 10 cigarettes per day 18. The subject consumes more than 10 units of alcohol per week (1 unit equals to 0.5 L of beer, 200 mL of wine or 50 mL of a strong alcohol beverage) or has a history of alcohol, recreational drug or medication abuse, or tests positive for alcohol and/or psychoactive substances during the screening examination 19. Donation of ≥ 450 mL of blood or plasma within 60 calendar days before signing the ICF. 20. Participation in any drug clinical studies within 30 calendar days prior to signing the informed consent form and through the entire period of study participation. \-

Design outcomes

Primary

Measure	Time frame	Description
AUC0-∞ of Eculizumab	from 0 to 1392 hours post-infusion	AUC0-∞ of eculizumab (the area under the Concentration vs. Time curve from 0 to infinity)

Secondary

Measure	Time frame	Description
Vd of Eculizumab	from 0 to 1392 hours post-infusion	Vd of eculizumab (steady-state volume of distribution)
Кel of Eculizumab	from 0 to 1392 hours post-infusion	Кel of eculizumab (elimination constant)
Cl of Eculizumab	from 0 to 1392 hours post-infusion	Cl of eculizumab (clearance)
AUC0-1392 of Eculizumab	from 0 to 1392 hours post-infusion	AUC0-1392 of eculizumab (the area under the Concentration vs. Time curve from 0 to 1392 h post-infusion)
Cmax of Eculizumab	from 0 to 1392 hours post-infusion	Cmax of eculizumab (maximum concentration of eculizumab in the serum)
Тmax of Eculizumab	from 0 to 1392 hours post-infusion	Тmax of eculizumab (time to Cmax)
Т1/2 of Eculizumab	from 0 to 1392 hours post-infusion	Т1/2 of eculizumab (half-life)
AUEC(0-1392) CH50	from 0 to 1392 hours post-infusion	AUEC(0-1392) CH50 ((area under the Time vs. Effect curve from 0 to 1392 h)
Emin CH50	from 0 to 1392 hours post-infusion	Emin CH50 (minimum hemolytic complement activity from 0 to 1392 h)
Tmin CH50	from 0 to 1392 hours post-infusion	Tmin CH50 (time to minimum hemolytic complement activity within the period from 0 to 1392 h)
Subjects With AEs/SAEs Related to Eculizumab	from 0 to 1392 hours post-infusion	The percentage of subjects with AEs/SAEs that, in the investigator's opinion, are related to eculizumab
Subjects Who Develop Grade 3/4 AEs Related to Eculizumab	from 0 to 1392 hours post-infusion	• The percentage of subjects with СТСАЕ v. 4.03 grade 3/4 AEs that, in the investigator's opinion, are related to eculizumab, by study arms.
ABEC(0-1392) CH50	from 0 to 1392 hours post-infusion	ABEC(0-1392) CH50 (the area between the baseline and effect curves for hemolytic activity of serum complement from 0 to 1392 h)

Countries

Russia

Participant flow

Participants by arm

Arm	Count
BCD-148 39 healthy subjects BCD-148: single 900 mg drip infusion given over 25-45 min BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5	39
Soliris 39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5	39
Total	78

Baseline characteristics

Characteristic	Total	BCD-148	Soliris
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	78 Participants	39 Participants	39 Participants
Age, Continuous	27 years	27 years	27 years
Race and Ethnicity Not Collected	0 Participants	—	—
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	78 Participants	39 Participants	39 Participants
Region of Enrollment Russia	78 participants	39 participants	39 participants
Sex: Female, Male Female	0 Participants	0 Participants	0 Participants
Sex: Female, Male Male	78 Participants	39 Participants	39 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 39	0 / 39
other Total, other adverse events	28 / 39	31 / 39
serious Total, serious adverse events	0 / 39	0 / 39